NCT00012298 2018-08-09
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Terminated
Clinical Trials
7 trialsNCT00438880 2016-02-04
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT00064246 2013-01-25
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00004048 2011-06-22
Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Phase 1/2 Completed
NCT00004087 2011-06-22
Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Phase 1/2 Completed
NCT00004107 2011-06-22
Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Phase 1/2 Completed
NCT00004177 2011-06-22
Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Phase 1/2 Completed